Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5781)
  3. Review (421)
  4. Editorial (196)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13278)
  2. Center for Hematologic Malignancies (10612)
  3. GSK Faculty (4482)
  4. Adult Leukemia (3673)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2705)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (340)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (330)
  5. Haematologica (292)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1530)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Induction with combined modality therapy followed by immunomodulated post remission therapy for newly diagnosed acute myeloid leukemia (AML)
    Meeting Abstract

    Gupta, S.; Weiss, M. A.; Jurcic, J. G.; Chanel, S.; Wilson, B. A.; Biederman, E.; Berman, E.; Scheinberg, D. A.; Maslak, P. G.
    Blood (2005)

    Fulltext@MSK | Save
  • Superior outcomes associated with earlier use: Experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin's lymphoma (NHL)
    Meeting Abstract

    Gregory, S. A.; Leonard, J. P.; Vose, J. M.; Zelenetz, A. D.; Horning, S. J.; Knox, S. J.; Lister, T. A.; Radford, J. A.; Press, O. W.; Kaminski, M. S.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Immunogenicity of a BCR-ABL e1a2 p190 translocation in a Balb/C mouse model
    Meeting Abstract

    Gómez-Nuñez, M.; Pinilla-Ibarz, J.; Dao, T.; Zakhaleva, V.; Korontsvit, T.; May, R. J.; Scheinberg, D. A.
    Blood (2005)

    Fulltext@MSK | Save
  • Reliability of computer algorithm-based binding predictions for the identification of leukemia antigens
    Meeting Abstract

    Gómez-Nuñez, M.; Pinilla-Ibarz, J.; Dao, T.; Korontsvit, T.; Zakhaleva, V.; May, R. J.; Scheinberg, D. A.
    Blood (2005)

    Fulltext@MSK | Save
  • The utility of gemcitabine and vinorelbine in patients with blastic NK lymphoma (CD4(+)/CD56(+) hematodermic neoplasm)
    Meeting Abstract

    Ellis, L. R.; Horwitz, S. M.
    Blood (2005)

    Fulltext@MSK | Save
  • A synthetic peptide, PCK3145, for the treatment of hormone refractory prostate cancer
    Meeting Abstract

    Daigneault, L.; Panchal, C.; Scher, H. I.; Slovin, S. F.; Rabbani, S.; Dulude, H.; Garde, S.; Ruiz, M.; Wu, J.; Hawkins, R.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Plasma cell gene-expression profiles in patients with systemic AL amyloidosis: Responses to melphalan and stem cell transplant are associated with differential expression of genes involved in translation, protein degradation and detoxification
    Meeting Abstract

    Comenzo, R. L.; Zhou, P.; Wang, L. M.; Nimer, S. D.; Olshen, A. B.
    Blood (2005)

    Fulltext@MSK | Save
  • Risk-adapted dosing of melphalan for systemic AL amyloidosis (AL) lowers treatment-related mortality: Early death but not post-3 month survival is linked to cardiac involvement
    Meeting Abstract

    Comenzo, R. L.; Zhou, P.; Hassoun, H.; Kewalramani, T.; Klimek, V.; Cohen, A. D.; Ferrand, S. K.; Dhodapkar, M.; Feldstein, J. T.; Fleisher, M.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Adjuvant dexamethasone (D)+/- thalidomide (T) improves hematologic and organ responses after risk-adapted high-dose melphalan with autologous stem cell transplant (SCT) for patients with systemic AL amyloidosis (AL)
    Meeting Abstract

    Cohen, A. D.; Zhou, P.; Reich, L.; Hassoun, H.; Teruya-Feldstein, J.; Filippa, D. A.; Fleisher, M.; Nimer, S. D.; Comenzo, R. L.
    Blood (2005)

    Fulltext@MSK | Save
  • Interim analysis of a phase II study of risk-adapted intravenous melphalan followed by adjuvant dexamethasone (D) and thalidomide (T) for newly diagnosed patients with systemic AL amyloidosis (AL)
    Meeting Abstract

    Cohen, A. D.; Zhou, P.; Reich, L.; Fircanis, S.; Drake, L.; Hedvat, C.; Teruya-Feldstein, J.; Filippa, D. A.; Fleisher, M.; Comenzo, R. L.
    Biology of Blood and Marrow Transplantation (2005)

    Fulltext@MSK | Save